| Study Number | Study Phase | Start Date | Recruitment Status |
ARI-IPEP-0104 | Non-interventional study | 15 Jan 2004 | Completed |
| AElectronic Study for Anastrozole Pharmacovigilance Evaluation. |
AST-ANA-2004-01 | Non-interventional study | 24 Jun 2004 | Active, not recruiting |
| Assessment of endometrial changes in postmenopausal women with breast cancer in adjuvant treatment with Anastrozole. |
1033AU/0001 ABCSG 6A | Phase III | 11-Dec-1995 | Completed |
| A randomized, open, comparative multicentre trial of 3 years anastrozole treatment vs. 3 years no treatment in postmenopausal patients with breast cancer who have completed 5 years adjuvant hormone therapy. |
| 1033AU/0002 ABCSG 8 | Phase III | 05-Jan-1996 | Completed |
| Adjuvant endocrine therapy in postmenopausal patients with HR +ve BC with good to moderate differentiation - ARNO (Arimidex + Nolvadex). Primary treatment for 2 years with tamoxifen thereafter randomisation to: tamoxifen 3 years or Anastrozole 3 years. |
| 1033AU/0003 ABCSG 16 | Phase III | 01-March-2004 | Recruiting |
| A prospective, randomized, open, multicentre phase III-study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further yrs vs 5 further yrs in patients with HR +ve breast cancer after 5-yr primary adjuvant endocrine therapy. |
1033GR/0001 ARNO | Phase III | 05-Dec-1996 | Active, not recruiting |
| A prospective, multi-centre, randomised, open parallel group study to compare the effectiveness and compatibility of ARIMIDEX (ZD 1033) with NOLVADEX after a prior 2 years’ treatment with tamoxifen in adjuvant therapy of breast carcinoma in postmenopausal women. |
1033GR/0002 | Phase IV | 10 Oct 2006 | Recruiting |
| Patient's Anastrozole Compliance to Therapy Programme (PACT): A randomised in practice evaluation of the influence of patient’s understanding of her disease and therapy on persistence and compliance to adjuvant therapy for post-menopausal hormone sensitivity. |
1033IA/0029 | Phase III | 8 Jun 1998 | Completed |
| A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
1033IC/0029 | Phase III | 1 Jun 1997 | Completed |
| A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
1033ID/0029 | Phase III | 10 Jun 1998 | Completed |
| A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabloism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
| 1033IE/0029 | Phase III | 07-Apr-1998 | Completed |
| A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life with Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
| 1033IL/0029 | Phase III | 12 Jul 1996 | Active, not recruiting |
| Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer |
| 1033IL/0039 | Phase III | 08-August-2000 | Completed |
| A randomised, double-blind, study comparing ARIMIDEX ™ with NOLVADEX ™ as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 (>3cm), T3, N0-2, M0) or potentially-operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer. |
| 1033IL/0046 | Phase II | 21 Aug 2002 | Completed |
| An Open-Label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome |
| 1033IT/0002 IT | Phase III | 03-March-1998 | Active, not recruiting |
| An Open Randomised Clinical Study Comparing ARIMIDEX™ with NOLVADEX™ as Adjuvant Therapies in Post-menopausal Women with Breast Cancer Already Being Treated with NOLVADEX for at Least Two Years |
| 1033MX/001 | Phase IV | 23-June-2003 | Recruiting |
| Neoadjuvant hormonal treatment of post-menopausal women who have operable breast cancer and whose tumours express hormonal estrogen receptors (ER) or Progesterone receptors (PgR), or both |
| D5391L00001 | Phase IV | 01-August-2004 | Completed |
| A Prospective,Open-Label Study of Anastrozole in Post-Menopausal Women With Hormone Sensitive Advanced Breast Cancer |
| D5392NL0002 ARREST | Phase IV, observational | 01-July-2004 | Completed |
| Arimidex; Reason for and effect of change from tamoxifen. The purpose of this study is to analyse the effect on Quality of Life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex |
| D5390000000 | Phase II | 17-Dec-2001 | Completed |
| An open, multicentre phase II trial assessing the objective response rate after combination of Arimidex® 1mg per os per day and Zoladex® 3.6 mg sub cutaneously monthly as first treatment for premenopausal receptor positive advanced or metastatic breast cancer |
| D5392C00050 SABRE | Phase III/(IV) | 01-Oct-2002 | Completed |
| A multicentre phase III/IV study, of the effects of risedronate sodium (ACTONEL™, 35mg/week, oral) on bone, in postmenopausal women, with hormone-receptor-positive early breast cancer, treated with anastrozole (ARIMIDEX™, 1mg/day oral) with either high-risk of fragility fracture (open-label, non-comparative stratum), or moderate-risk of fragility fracture (randomised, double-blind stratum), and of the effects of anastrozole (ARIMIDEX™, 1mg/day oral) on bone, in postmenopausal women, with hormone-receptor-positive early breast cancer, and low-risk of fragility fracture (open-label, non-comparative stratum) |
| D5392L00013 | Phase IV | 15-Jun-2006 | Recruiting |
| A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/day) as Adjuvant Treatment in Post Menopausal Women with Early Breast Cancer |
| D5392L00023 | Phase IV | 18-Sept-2007 | Recruiting |
| A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX™ Compared with Tamoxifen in Adjuvant Therapy in Postmenopausal Women with Hormone Receptor+ Early Breast Cancer. |
| D5392NL0003 DATA | Phase III | March 2006 | Recruiting |
| A prospective randomised, open, multicentre, phase III study to assess different durations of anastrozole therapy after 2 to 3 years tamoxifen as adjuvant therapy in postmenopausal women with breast cancer. |
| D5394C00001 | Phase II | 05-May-2005 | Completed |
| An open-label pharmacokinetic and pharmacodynamic study of anastrazole (Arimidex™) used to treat pubertal boys with gynecomastia of recent onset |
| D539BC00001 | Phase II/III | 03-Oct-2007 | Recruiting |
| Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-Operative Administration Under Luteinising Hormone-Releasing Hormone Agonist Treatment for Premenopausal Breast Cancer Patients |
| Non-interventional study | 25 Feb 2008 | Recruiting |
| Breast Cancer Tumorcare Observation Progamme |
| Non-interventional study | 25 Feb 2008 | Recruiting |
| Breast Cancer Tumorcare Observation Progamme |
| Non-interventional study | 30 Sep 2008 | Recruiting |
| A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence with Adjuvant Aromatase Inhibitors (AI) medication for Postmenopausal, Early Stage Breast Cancer |
| NIS-OHU-ARI-2007/1 | Non-interventional study | 14 May 2007 | Recruiting |
| QUALITY OF LIFE ANALYSIS OF ARIMIDEX TREATMENT IN POSTMENOPAUSAL PATIENTS WITH BREAST CANCER |
| NIS-OIT-DUM-2006/1 | Non-interventional study | 1 Jul 2007 | Completed |
| Retrospective observational trial on reasons for withdraw of Adjuvant Tamoxifen in Breast Cancer patients |